More Blood Pressure Drugs Added to Valsartan Recall List

Fact-Checked

Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Man reaching for prescription pills

Mylan and Teva Pharmaceuticals — two large generic drug manufacturers — expanded their U.S. valsartan recalls in November because of contamination with a cancer-causing chemical called N-nitrosodiethylamine (NDEA).

Teva’s recall notice called NDEA a “probable human carcinogen.” The company said the impurity had been detected in an active pharmaceutical ingredient (API) from Mylan Laboratories Limited in India.

Drugs included in Teva’s recall are:

  • amlodipine and valsartan combination tablets
  • amlodipine, valsartan and hydrochlorothiazide combination tablets

The nearly 50 lots that are part of the recall had been packed in bottles and distributed to wholesalers, distributors, retailers, repackagers, VA pharmacies and other accounts nationwide.

“To date, Teva has not received any reports of adverse events signaling a potential link or exposure to valsartan,” Teva said in its recall notice. “Patient safety and product quality is critical to Teva. As always, Teva will continue to partner with, and regularly update, all relevant stakeholders, including regulatory authorities, to resolve this situation.”

The company also advised people not to stop taking their medication because “the risk of harm to a patient’s health may be higher if the treatment is stopped immediately without any comparable alternative treatment.” Patients who take valsartan-containing medications should contact their pharmacist or doctor for advice on what to do next.

U.S.-based Mylan Pharmaceuticals also recalled 15 lots of valsartan because of NDEA contamination. Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited manufactured the drugs, which were distributed in the U.S. between March 2017 and November 2018.

Drugs included in Mylan’s recall are:

  • amlodipine and valsartan tablets
  • valsartan tablets
  • valsartan and hydrochlorothiazide tablets

Before they detected NDEA in their drug supply, valsartan makers had originally recalled batches of the drug in July because they were contaminated with N-nitrosodimethylamine (NDMA), another known cancer-causing agent.

Diagnosed with cancer after Valsartan use? Get a Free Case Review

The first contaminated APIs came from a manufacturer in China, Zhejiang Huahai Pharmaceuticals. The company supplied the tainted drug to several U.S.-based companies.

In September, the U.S. Food and Drug Administration announced that it had stopped all drugs made by Zhejiang Huahai Pharmaceuticals from entering the United States. Some patients have begun filing cancer lawsuits against valsartan companies.

The recall has since spread to two other generic drugs in the same drug class as valsartan — irbesartan and losartan — because of NDEA contamination. The FDA maintains a separate recall list of ibesartan drugs on its website.

So far, only Sandoz has recalled a single lot of losartan potassium hydrochlorothiazide tablets. The company said it has not received any adverse events related to the lot.

The FDA said it is taking the threat to patients’ safety seriously. The agency has hired chemists to monitor and review drug companies and their manufacturing processes to prevent more impurities from entering the drug supply, FDA Commissioner Scott Gottlieb told USA Today.

The agency continues to investigate the manufacturing problem that led to the recalls.

“The FDA has determined the recalled lots of valsartan, irbesartan, and losartan products pose an unnecessary risk to patients,” the agency said in a Q&A on the FDA website. “All products found to contain these impurities have been recalled and are no longer available in the U.S. market. Our investigation and testing activities are ongoing.”

  •  
  •  
  •  
Michelle Llamas, Senior Content Writer
Written By Michelle Llamas Senior Writer

Michelle Llamas has been writing articles and producing podcasts about drugs, medical devices and the FDA for seven years. She specializes in fluoroquinolone antibiotics, vaccines and products that affect women’s health such as Essure birth control, transvaginal mesh and talcum powder. Michelle collaborates with experts, including board-certified doctors, patients and advocates, to provide trusted health information to the public. Some of her qualifications include:

  • American Medical Writers Association (AMWA) Engage Committee and Membership Committee member
  • Centers for Disease Control and Prevention (CDC) Health Literacy certificates
  • Original works published or cited in The Lancet, British Journal of Clinical Pharmacology and the Journal for Palliative Medicine
Edited By

7 Cited Research Articles

  1. U.S. Food and Drug Administration. (2018, November 20). Mylan Initiates Voluntary Nationwide Recall of 15 Lots of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient. Retrieved from https://www.fda.gov/Safety/Recalls/ucm626367.htm
  2. U.S. Food and Drug Administration. (2018, November 27). Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry. Retrieved from https://www.fda.gov/Safety/Recalls/ucm626802.htm
  3. U.S Food and Drug Administration. (2018, November 8). Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API). Retrieved from https://www.fda.gov/Safety/Recalls/ucm625492.htm
  4. Alltucker, K. (2018, November 14). FDA chief: Blood pressure medicine recalls reflect increased scrutiny on drug safety. Retrieved from https://www.usatoday.com/story/news/health/2018/11/14/fda-commissioner-scott-gottlieb-drug-recalls-iosartan-valsartan-irbesartan/2000575002/
  5. U.S Food and Drug Administration. (n.d.). Questions and Answers: Impurities found in certain generic angiotensin II receptor blocker (ARB) products. Retrieved from https://www.fda.gov/Drugs/DrugSafety/ucm626122.htm
  6. Erman, M. (2018, September 18). FDA halts imports from China's Huahai Chuannan plant. Retrieved from https://www.reuters.com/article/us-huahai-pharm-imports/fda-halts-imports-from-chinas-huahai-chuannan-plant-idUSKCN1M821U
  7. U.S Food and Drug Administration. (n.d.). Ibesartan products under recall – Updated October 29, 2018. Retrieved from https://www.fda.gov/downloads/Drugs/DrugSafety/UCM624627.pdf
View All Sources
Call to speak with a legal expert
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(877) 239-9641